Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (57)

2021

  1. Article a multicenter analysis of the outcome of cancer patients with neutropenia and covid-19 optionally treated with granulocyte-colony stimulating factor (G-csf): A comparative analysis

    Cancers, Vol. 13, Núm. 16

2020

  1. Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer

    Cancer Biology and Medicine, Vol. 17, Núm. 2, pp. 444-457

2017

  1. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

    Tumor Biology, Vol. 39, Núm. 6

  2. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy

    BMC Cancer, Vol. 17, Núm. 1

2015

  1. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer

    PLoS ONE, Vol. 10, Núm. 1

  2. Gene expression differences in primary colorectal tumors and matched liver metastases: chemotherapy related or tumoral heterogeneity?

    Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 322-329

  3. SMAD4 and TS expression might predict the risk of recurrence after resection of colorectal liver metastases

    Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 133-138

2014

  1. First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

    British Journal of Cancer, Vol. 111, Núm. 2, pp. 241-248

2013

  1. SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013

    Clinical and Translational Oncology, Vol. 15, Núm. 12, pp. 996-1003

2012

  1. Expression profile as predictor of relapse after adjuvant treatment in gastric cancer

    Journal of Gastrointestinal Cancer, Vol. 43, Núm. 2, pp. 181-189

  2. Internet use by cancer patients: Should oncologists 'prescribe' accurate web sites in combination with chemotherapy? A survey in a spanish cohort

    Annals of Oncology, Vol. 23, Núm. 6, pp. 1579-1585

  3. Management of colorectal cancer patients after resection of liver metastases: Can we offer a tailored treatment?

    Clinical and Translational Oncology, Vol. 14, Núm. 9, pp. 641-658

  4. Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target

    International Journal of Radiation Oncology Biology Physics, Vol. 84, Núm. 5, pp. 1151-1158

2011

  1. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy

    Colorectal Disease, Vol. 13, Núm. 9, pp. 989-998

2009

  1. Angiogenesis and ovarian cancer

    Clinical and Translational Oncology, Vol. 11, Núm. 9, pp. 564-571

  2. Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use

    Cancer Treatment Reviews, Vol. 35, Núm. 3, pp. 246-254

  3. Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: Multicenter phase II study

    Cancer Chemotherapy and Pharmacology, Vol. 63, Núm. 3, pp. 403-409

  4. EPO-R expression patterns in resected gastric adenocarcinoma followed by adjuvant chemoradiation treatment

    Pathology and Oncology Research, Vol. 15, Núm. 1, pp. 1-10

  5. KRAS mutations in primary colorectal cancer tumors and related metastases: A potential role in prediction of lung metastasis

    PLoS ONE, Vol. 4, Núm. 12

  6. Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy

    International Journal of Colorectal Disease, Vol. 24, Núm. 7, pp. 741-748